When the Model Is Confident and the Patient Is Not

Sep 29, 2026 | News

Image Source: Joseph Akbrud / Unsplash
Independent Contributor
Written by: Harvey Castro, MD, MBA, Emergency Medicine Physician
On behalf of: N/A

It is 2:07 a.m. in the emergency department. The waiting room is thin. The hallway is not. A middle-aged man looks pale. His vitals sit in the green band. A clinical decision support tile on the chart says low risk with a high confidence score. His wife keeps saying he is not himself. That gap, between a confident model and a scared family, is where overnight emergency care actually lives.

I am a practicing emergency physician. Demo day and overnight care are not the same stress test. What breaks first is rarely the algorithm’s receiver operating characteristic (ROC) curve. What breaks first is the handoff: who saw the alert, who owns the next action, and whether the bedside clinician still feels free to disagree.

The handoff, not the demo

Health systems often evaluate clinical AI the way we evaluate a new ultrasound probe: show a clean case, measure accuracy, celebrate. Overnight emergency medicine adds friction the demo never feels. The nurse who acknowledged the alert may not be the one who can order the CT. The resident who opened the chart may already be in another room. The attending may see the recommendation after the family conversation has already started.

A 2026 systematic review of predictive AI clinical decision support across specialties found moderate pooled discrimination, but a sharp gap between technical validation and real-world use. Most included studies reported only technical metrics. Among the minority that reported alert response data, override rates ranged from roughly 12% to 38%. Clinician adoption, when reported at all, varied widely.[1] That spread is not a marketing problem. It is a workflow problem.

Emergency clinicians have said as much in mixed-methods work on AI decision support in the emergency department (ED): performance on typical cases is not enough if alerts create fatigue, if atypical cases behave differently, and if the interface can bias judgment both when it fires and when it stays silent.[2] The first failure mode I watch for is not “the model was wrong.” It is “the model was right enough to look finished, and the care team never finished the human loop.”

When vitals look fine and the family is scared

Model confidence is not clinical certainty. Calibration research has made that distinction blunt: a prediction can sort patients well and still misstate how often the event actually happens. For bedside decisions, that miscalibration matters more than a pretty area under the curve (AUC).[3]

At 2 a.m., the conflict is often qualitative. The numbers look reassuring. The history does not. A spouse notices a change in speech. A parent will not leave the bedside. Those cues are not in every training set. They still change disposition.

Automation bias (over-reliance on imperfect decision support) is not a new story. A systematic review found that erroneous decision-support advice raised the risk of an incorrect decision, and that time pressure, workload, and trust all shape how hard the advice sticks.[4] Safety writers later framed the same risk for machine-learning tools: automation complacency is strongest when a system has usually been reliable, the clinician is loaded with concurrent tasks, and the shift is late.[5]

Experimental work sharpens the point. In a study of emergency-style decisions, both clinicians and non-experts followed biased advice more readily when it was framed as a prescription (“you should do X”) than when it was framed as a descriptive flag. Style of presentation changed adherence.[6] Other clinician-facing work found that people do not only accept or reject AI treatment advice. They often negotiate it: take part of the recommendation, delay another part, or ignore a piece that does not fit the case.[7] That negotiation is clinical judgment. A confidence score that looks like a verdict can quietly shrink the space for it.

None of this means clinical decision support has no place in the ED. It means confidence without a clear path for dissent is a safety risk, not a feature.

Who owns the last mile when the recommendation is wrong

When a recommendation is wrong, patients and families do not care which slide deck looked best. They ask who was responsible for the last mile.

U.S. regulators have been clear that some clinical decision support is outside device oversight only when clinicians can independently review the basis for the recommendation and are not meant to rely primarily on the software. Time-critical tasks make that independent review harder, which is why overnight acute care sits in a different risk band than a leisurely outpatient prompt.[8] Health-delivery organizations also face a practical bind: tools that pull frequent vital signs or push singular, urgent outputs may cross into regulated device territory, which shifts validation and monitoring duties onto the system that deploys them.[9]

Liability analyses land in a similar place. Physicians keep malpractice duties around whether their use of a tool met the standard of care. Health systems can face risk for negligent selection, validation, training, or monitoring. Software makers can face product or contract claims. No single actor absorbs the whole chain by default.[10][11]

In practice, that means contracts and governance matter as much as model cards. Who documents an override? Who reviews silent misses? Who can turn the tool off at 3 a.m. without waiting for a committee? If those answers are fuzzy, ownership is already broken before any lawsuit starts.

I do not treat these questions as anti-innovation. They are the minimum for putting a recommendation in front of a tired clinician and a frightened family.

What to measure next

If researchers and health-tech teams want tools that survive overnight care, they should stop treating accuracy alone as the finish line. Measure the work around the model.

Useful next metrics include:

  1. Handoff completion. Was the alert seen by someone who could act, and was the next step named?
  2. Override rate with reason codes. Not only how often clinicians disagree, but why (wrong patient context, known contraindication, family concern, data lag, mistrust of calibration).
  3. Silent-failure review. Cases where no alert fired and the clinical course later showed risk the tool was supposed to catch.
  4. Escalation latency. Time from alert or bedside concern to a decision owner with authority.
  5. Presentation style effects. Prescriptive versus descriptive framing, and whether confidence scores shrink healthy negotiation.
  6. Calibration drift by site and subgroup. Discrimination is not enough if predicted risk no longer matches observed events after deployment.[1][3]

A recent multicenter trial of computerized diagnostic decision support in emergency patients did not show superiority over usual diagnosis on its primary diagnostic-quality outcome. That result is a reminder: tools that look strong on differential lists still have to prove patient-relevant benefit in messy acute care.[12]

Educational frame only: none of this is a bedside protocol, and none of it replaces local credentialing, legal counsel, or institutional governance. The point is simpler. Overnight emergency medicine will keep exposing the gap between model confidence and patient reality. Teams that measure handoffs, overrides, and ownership will learn faster than teams that only polish the demo.

The model can be confident. The patient, and the family, may not be. Our job is to keep judgment, escalation, and accountability in the room when those two facts collide.

 

Author Bio

    Harvey Castro, MD, MBA, is a board-certified emergency physician practicing in the Dallas-Fort Worth area. He previously served as CEO of eight freestanding emergency rooms and is a five-time TEDx speaker. Dr. Castro is the author of AI in Emergency Medicine (Wiley, 2026) and ChatGPT and Healthcare: The Key to the New Future of Medicine (2023). He is Advisor to the CEO of Phantom Space. He writes and speaks on clinical AI, overnight workflows and last-mile accountability in acute care.
    References:
    1. Waldock WJ, Guni A, Darzi A, Ashrafian H. Performance of predictive AI-based clinical decision support systems across clinical domains: a systematic review and meta-analysis. PLOS Digital Health. 2026;5(3):e0001310. https://doi.org/10.1371/journal.pdig.0001310
    2. Fujimori R, Liu K, Soeno S, et al. Acceptance, barriers, and facilitators to implementing artificial intelligence-based decision support systems in emergency departments: quantitative and qualitative evaluation. JMIR Formative Research. 2022;6(6):e36501. https://doi.org/10.2196/36501
    3. Van Calster B, McLernon DJ, van Smeden M, Wynants L, Steyerberg EW; Topic Group 'Evaluating diagnostic tests and prediction models' of the STRATOS initiative. Calibration: the Achilles heel of predictive analytics. BMC Medicine. 2019;17:230. https://doi.org/10.1186/s12916-019-1466-7
    4. Goddard K, Roudsari A, Wyatt JC. Automation bias: a systematic review of frequency, effect mediators, and mitigators. Journal of the American Medical Informatics Association. 2012;19(1):121-127. https://doi.org/10.1136/amiajnl-2011-000089
    5. Challen R, Denny J, Pitt M, Gompels L, Edwards T, Tsaneva-Atanasova K. Artificial intelligence, bias and clinical safety. BMJ Quality & Safety. 2019;28(3):231-237. https://doi.org/10.1136/bmjqs-2018-008370
    6. Adam H, Balagopalan A, Alsentzer E, Christia F, Ghassemi M. Mitigating the impact of biased artificial intelligence in emergency decision-making. Communications Medicine. 2022;2:149. https://doi.org/10.1038/s43856-022-00214-4
    7. Sivaraman V, Bukowski LA, Levin J, Kahn JM, Perer A. Ignore, trust, or negotiate: understanding clinician acceptance of AI-based treatment recommendations in health care. Proceedings of the 2023 CHI Conference on Human Factors in Computing Systems. ACM; 2023. https://doi.org/10.1145/3544548.3581075
    8. U.S. Food and Drug Administration. Clinical Decision Support Software: Guidance for Industry and Food and Drug Administration Staff. 28 September 2022. https://www.fda.gov/media/109618/download
    9. Sendak MP, Liu VX, Beecy A, et al. Strengthening the use of artificial intelligence within healthcare delivery organizations: balancing regulatory compliance and patient safety. Journal of the American Medical Informatics Association. 2024;31(7):1622-1627. https://doi.org/10.1093/jamia/ocae119
    10. Mello MM, Guha N. Understanding liability risk from using health care artificial intelligence tools. New England Journal of Medicine. 2024;390(3):271-278. https://doi.org/10.1056/NEJMhle2308901
    11. Price WN II, Gerke S, Cohen IG. Potential liability for physicians using artificial intelligence. JAMA. 2019;322(18):1765-1766. https://doi.org/10.1001/jama.2019.15064
    12. Hautz WE, Marcin T, Hautz SC, et al. Diagnoses supported by a computerised diagnostic decision support system versus conventional diagnoses in emergency patients (DDX-BRO): a multicentre, multiple-period, double-blind, cluster-randomised, crossover superiority trial. The Lancet Digital Health. 2025. https://doi.org/10.1016/S2589-7500(24)00250-4
    All content is published for informational purposes only and does not constitute medical, legal, or investment advice. For more information, see our Terms and Conditions

    Articles that may be of interest

    Weekly News Roundup | 2 November 2026

    Weekly News Roundup | 2 November 2026

    Life science news 2 November 2026: four approvals, three deals and a UK Budget investment package. Ferring has agreed to acquire Gameto in a deal worth up to $1.3825bn. The FDA granted accelerated approval to Voceryq for recurrent respiratory papillomatosis. The MHRA...

    read more
    Eppendorf and BioLabs Expand Collaboration to Munich

    Eppendorf and BioLabs Expand Collaboration to Munich

    The collaboration will provide laboratory equipment, technical support and engagement opportunities for BioLabs resident companies. It builds on existing partnerships at BioLabs sites across the US, Germany and France. HAMBURG and MUNICH, Germany, 21 October 2026...

    read more
    Weekly News Roundup | 26 October 2026

    Weekly News Roundup | 26 October 2026

    Life science news 26 October 2026: two major deals, three US approvals, two UK updates and a reverse merger. Roche signed an antibody-drug conjugate deal with Hansoh. Merck KGaA agreed to buy Silence Therapeutics for about $1.3bn. The FDA granted accelerated approval...

    read more

    Articles that may be of interest

    Weekly News Roundup | 2 November 2026

    Weekly News Roundup | 2 November 2026

    Life science news 2 November 2026: four approvals, three deals and a UK Budget investment package. Ferring has agreed to acquire Gameto in a deal worth up to $1.3825bn. The FDA granted accelerated approval to Voceryq for recurrent respiratory papillomatosis. The MHRA...

    read more
    Eppendorf and BioLabs Expand Collaboration to Munich

    Eppendorf and BioLabs Expand Collaboration to Munich

    The collaboration will provide laboratory equipment, technical support and engagement opportunities for BioLabs resident companies. It builds on existing partnerships at BioLabs sites across the US, Germany and France. HAMBURG and MUNICH, Germany, 21 October 2026...

    read more
    Weekly News Roundup | 26 October 2026

    Weekly News Roundup | 26 October 2026

    Life science news 26 October 2026: two major deals, three US approvals, two UK updates and a reverse merger. Roche signed an antibody-drug conjugate deal with Hansoh. Merck KGaA agreed to buy Silence Therapeutics for about $1.3bn. The FDA granted accelerated approval...

    read more